← Eichor
Study identifier: NCT07361471 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Condition: Ovarian Cancer  ·  Sponsor: Centre Jean Perrin

PhaseNA
Planned participants55
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

This description comes directly from the study's public registry record.

Talk to the study team

Judith PASSILDAS JAHANMOHAN, PhD  ·  0463663337  ·  judith.passildas@clermont.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Jean PerrinClermont-Ferrand, PUY DE DOME, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07361471